BioSpace News Archive

Global molecular diagnostics innovator, Sense Biodetection, announced it has entered into a strategic agreement with TECOmedical for the non-exclusive distribution of Sense’s Veros COVID-19, the first test on the rapid, instrument-free, point-of-care Veros molecular testing platform.

AiCuris Anti-infective Cures AG, a leading company in the discovery and development of drugs against infectious diseases, announced the appointment of Dr. Sabrina Kuttruff-Coqui as Chief Financial Officer, effective September 1, 2022.

MannKind Corporation announced that its Chief Executive Officer, Michael Castagna, PharmD, will participate in a Fireside Chat at the H.C. Wainwright 24th Annual Global Investment Conference on Tuesday, September 13, 2022 at 12:00 PM ET at the Lotte New York Palace Hotel.

Fluidx Medical announces completion of trial enrollment for its novel embolic device, GPX.

Cerveau Technologies, Inc. announced a research collaboration agreement with Alnylam® Pharmaceuticals, which will enable Alnylam to use Cerveau’s [F-18]MK-6240, an investigational imaging agent, in Positron Emission Tomography scans to assess the status and progression of neurofibrillary tangles in the brain.

Castle Biosciences, Inc. announced that Derek Maetzold, president and chief executive officer, and Frank Stokes, chief financial officer, are scheduled to present a company overview at Baird’s 2022 Global Healthcare Conference on Tuesday, Sept. 13, 2022, at 2:00 p.m. Eastern time.

Ocugen, Inc. (Ocugen or the Company) (NASDAQ: OCGN), a biotechnology company focused on discovering, developing, and commercializing novel gene and cell therapies and vaccines, today announced the appointment of Robert J. Hopkins, MD, MPH & TM, FACP, FIDSA, as Chief Medical Officer.

Deciphera Pharmaceuticals, Inc. (NASDAQ: DCPH), today announced that it will host a virtual investor event to review clinical data from the Company’s DCC-3116 and vimseltinib programs to be presented at the upcoming European Society for Medical Oncology (ESMO) Congress 2022 on Sunday, September 11, 2022, from 7:30 AM to 9:30 AM ET / 1:30 PM CEST to 3:30 PM CEST.

KemPharm, Inc. (NasdaqGS: KMPH) (KemPharm, or the Company), today announced that Travis C. Mickle, Ph.D., President and CEO of KemPharm, will deliver a virtual presentation at the H.C. Wainwright 24th Annual Global Investment Conference being held from September 12-14, 2022, in New York, New York.

Finch Therapeutics Group, Inc., a clinical-stage microbiome therapeutics company leveraging its Human-First Discovery® platform to develop a novel class of orally administered biological drugs, announced plans to reduce its workforce by approximately 37% as part of an ongoing strategic review of its business and portfolio.